Healthcare & Life Sciences Insights

Discover Latham’s latest insights into the commercial, regulatory, and legal developments shaping the global healthcare and life sciences landscape.

Latham’s cross-disciplinary team delivers insightful, practical guidance and sophisticated representation to a full spectrum of healthcare and life sciences companies across the globe, on every type of transaction or dispute a company may face.

Learn more about our capabilities

August 6, 2026 Client Alert

FDA on Peptides: A New Landscape for Compounders

Close-up of vegetables, fruits, and nuts on gray background.

August 18, 2026 Client Alert

FDA Proposes to Mandate GRAS Notices for Food Substances

Close-up digital rendering of molecular structure.

July 1, 2026 Our Work

Latham & Watkins Advises BridgeBio on Up to US$1 Billion Preferred Equity Investment, One of the Largest Preferred Investments for Public Biotechs Ever and the Largest in 2026

Blister pack of red and white pill capsules.

June 5, 2026 Client Alert

UK Reforms Clinical Trials Regulations

Digitally rendered gel capsule filled with multicolor spheres.

May 13, 2026 Podcast

Drug Pricing and Market Access: CMS Update With Rujul Desai

August 24, 2026 Newsletter

Healthcare & Life Sciences: Drug Pricing Digest — Number 79

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law.

August 18, 2026 Client Alert

FDA Proposes to Mandate GRAS Notices for Food Substances

The proposed rule would convert the voluntary Generally Recognized as Safe notification program to a mandatory one, with significant implications for food manufacturers.

August 10, 2026 Newsletter

Healthcare & Life Sciences: Drug Pricing Digest — Number 78

August 6, 2026 Client Alert

FDA on Peptides: A New Landscape for Compounders

July 28, 2026 Client Alert

FDA Revises Draft Guidance on Demonstrating Substantial Evidence of Effectiveness

Medium angle of the East Front of The US Capitol Building at sunset.

June 25, 2026

Under the Spotlight: Navigating Congressional Investigations Before and After the Upcoming Midterm Elections

Latham’s bipartisan Congressional Investigations team examine the evolving landscape of congressional oversight in an election year. MCLE credit offered.

May 13, 2026

Drug Pricing and Market Access: CMS Update With Rujul Desai

Senior Counselor to CMS, Rujul Desai, joins the Latham team to share updates on a host of current policy topics, from most favored nation pricing and TrumpRx to 340B and program integrity initiatives.

May 12, 2026

DOJ Ramps Up Enforcement on Customs and Tariff Fraud: What Global Companies Need to Know to Mitigate Risk

Latham lawyers discuss what global companies need to know to mitigate risk related to DOJ’s enforcement on customs and tariff fraud. MCLE credit offered.

April 27, 2026

Drug Pricing and Market Access: Highlights From Recent CMS and AHLA Conferences

Missed the CMS Quality Conference or the AHLA Institute on Medicare and Medicaid Payment Issues? Join the Latham team for a discussion of highlights from both events.

Close-up of electrocardiogram (ECG) machine readout.

January 22, 2026

DOJ Enforcement Priorities: What Medical Device Companies Need to Know

Latham lawyers offer practical insights for medical device companies on mitigating enforcement risk and implementing defense strategies. MCLE credit offered.

January 16, 2026

Latham & Watkins M&A Leaders on the ‘Year of the Mega Deal’

Latham partners Alex Kelly and Paul Kukish, Global Co-Chairs of the firm’s M&A and Private Equity Practice, discuss the surge in global mega deal activity that propelled Latham to the top spot in 2025 M&A and private equity league tables and what’s shaping the deal landscape for 2026.

December 17, 2025

FDA’s QMSR Implementation Is Around the Corner: What Medical Device Companies Need to Know to Be Ready

Latham’s FDA practitioners discuss the new Quality Management System Regulation and what it means for medical device manufacturers, importers, and other stakeholders. MCLE credit offered.

December 16, 2025

Drug Pricing and Market Access: “Think of It as a Loop” — Succeeding in an Evolving Policy Landscape

Join the Latham team and guest Mike Domanico, a veteran of the pharmaceutical industry, for insights on how organizations can not only survive, but thrive in an ever-shifting policy landscape.

Close-up of blue and white pills capsules.

December 15, 2025

Episode 106 — The FDA’s New Playbook: Biosimilars, National Priority Vouchers, and the Plausible Mechanism Pathway

The Latham team unpacks the FDA’s recent actions on the Commissioner’s National Priority Voucher program, the plausible mechanism pathway, and biosimilars — and what they could mean for development timelines, pricing, and market access.

November 24, 2025

Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits

Join the Latham team and guest Eliza Biedziak from Ernst & Young LLP as they discuss what to expect from a government pricing assessment, the role assessments play in compliance, and how assessments can uncover strategic opportunities.

November 03, 2025

Drug Pricing and Market Access: Deep Dive on the FDA Commissioner’s National Priority Voucher Program Awards

FDA just announced nine awards under the new CNPV program, based in part on drug pricing and onshoring of manufacturing. We review the awards in detail, consider possible agency rationale, and investigate broader implications on pharmaceutical pricing, launch strategies, and market transparency.

October 02, 2025

Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit

The largest drug pricing conference of the year just concluded in Chicago. Join the Latham team to discuss key themes and highlights, including most favored nation pricing considerations, bona fide service fee changes, and 340B program developments.

Digitally rendered image electrocardiograph line.

July 30, 2025

Healthcare Implications of the One Big Beautiful Bill: What You Need to Know

Members of Latham’s Healthcare & Life Sciences Practice discuss impacts of the OBBB’s healthcare policy provisions. MCLE credit offered.

June 24, 2025

Drug Pricing: Takeaways From the Philadelphia Pricing and Contracting USA Conference

Join the Latham team and Allan Thoen from Sandoz to hear about the key themes and highlights from one of the year’s significant drug pricing conferences.

Abstract background of wires and glowing particles

June 26, 2025

Access Denied — Navigating the New DOJ Data Security Program With Confidence

Latham’s team of lawyers focusing on data security and national security examine DOJ’s DSP and its potential implications for companies. MCLE credit offered.

June 06, 2025

Drug Pricing: Takeaways From the MDMA Annual Meeting

One of the country’s largest medical innovation and policy conferences recently concluded in Washington, D.C. Join the Latham team to discuss takeaways from the meeting, including regulatory changes and compliance hot topics.